Server: Netscape-Commerce/1.1 Date: Thursday, 18-Dec-97 18:21:18 GMT Last-modified: Thursday, 30-Oct-97 15:29:01 GMT Content-length: 10206 Content-type: text/html Press Releases for OraVax Inc.
10/29/97 OraVax, Inc. to Conduct Phase III Clinical Trial for Respiratory Syncytial Virus in Infants in Winter 1998-1999

10/23/97 OraVax, Inc. Reports 1997 Third Quarter Results
-- Company Enters Yellow Fever U.S. Marketing and Distribution Agreement with Evans Medical Limited and Acquires ChimeriVaxTM Technology Platform --

10/20/97 NIH Awards OraVax Phase II SBIR Grant for the Clinical Development of New Treatments for Clostridium difficile Associated Disease

09/29/97 OraVax and Evans Medical Sign U.S. Marketing and Distribution Agreement for Yellow Fever Vaccine
-- OraVax To Assist With U.S. Registration –

09/16/97 OraVax Acquires Chimeric Vaccine Technology from St. Louis University
-- Patent Filing Covers a New Class of Single-Dose Viral Vaccines --

07/30/97 OraVax, Inc. Announces 1997 Second Quarter and Six Month Results

04/25/97 OraVax, Inc. Announces 1997 First Quarter Results

04/04/97 OraVax, Inc. Adopts Shareholder Rights Plan

04/03/97 OraVax Announces Reorganization; Reduces Operating Costs
--Robert J. Gerety, M.D., Ph.D., Named Vice President of Development and Regulatory Affairs--

03/19/97 OraVax Reports Results from Phase III Trial of HNK20 Nosedrop for Respiratory Syncytial Virus in Infants

03/10/97 OraVax names C. Boyd Clarke, President of U.S. Bioscience, to Board of Directors.
-- Engineered Joint Venture Between Merck and Pasteur-Mérieux --

03/03/97 OraVax Reports Fourth-Quarter and Year-End results
-- Clinical Progress in Two Lead Programs Highlight Year --

11/25/96 Complete H. Pylori Genome Sequence Licensed to OraVax And Pasteur Mérieux Connaught in Exclusive agreement with MedImmune and Human Genome Sciences for Development of Novel Vaccines

11/14/96 OraVax Grants bioMérieux Vitek License to CagA Antigen For H. pylori  In Vitro Diagnostic Tests
-- Out-Licensing Strategy Complements Core Vaccine Development --

10/23/96 Oravax Reports 1996 Third Quarter Results
-- Successful Phase II Trial of Oral Therapeutic Vaccine Against H. pylori and Progress in Phase III Trial of HNK-20 Highlight Quarter --

10/17/96 OraVax and Pasteur Mérieux Connaught Demonstrate Reduction of H. pylori Infection in Subjects Receiving Oral Vaccine
-- Clinical Study Demonstrates Immune Responses and Reduced H. pylori Infection --

09/26/96 OraVax Updates Investors at Cowen & Company's 11th Annual Biotechnology Conference
-- Phase 2 safety and immunogenicity study of H. pylori  oral vaccine complete; data to be presented at October H. pylori  conference --

08/07/96 OraVax, Inc. Reports 1996 Second Quarter Results
-- Commencement of Phase 3 trials and regional marketing partnership for HNK20 highlight quarter --

08/05/96 U.S. Patent Issues For OraVax, Inc.'s Oral Treatment of H. pylori  Infection

07/08/96 OraVax, Inc. Announces Exercise of Over-Allotment Option

06/26/96 OraVax, Inc. Announces Public Offering of 2.0 Million Shares of Common Stock


OraVax Home Page| Annual Report Highlights| Contacting Us
Current Stock Price| About OraVax